Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

Taofeek K. Owonikoko,Stéphane Champiat,Melissa Lynne Johnson,Ramaswamy Govindan,Hiroki Izumi,W. Victoria Victoria Lai,Hossein Borghaei,Michael Boyer,Rene J. Boosman,Horst-Dieter Hummel,Fiona H Blackhall,Noemi Reguart,Afshin Dowlati,Yiran Zhang,Sujoy Mukherjee,Mukul Minocha,Yanchen Zhou,Aditya Shetty,Nooshin Hashemi Sadraei,Luis Paz-Ares

Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

2021

8510Background: DLL3, an inhibitory Notch ligand, is a promising target as it is highly expressed in SCLC compared to normal tissue. AMG 757, a half-life extended BiTE immuno-oncology therapy, bind...

Keywords:

non small cell
Inhibitory postsynaptic potential
Medicine
Half-life
normal tissue
Cancer research
Notch ligand
delta like ligand
T cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations